Development and Validation of Stability Indicating HPTLC Methods for the Estimation of Antihypertensive Drugs (Nebivolol and Hydrochlorothiazide)

Anamika; Roshan Kumar; Subham Kumar; Priya Singh; Puja Kumari; Abhishek Kumar; Rajeev Ranjan Raj; Kritika Singh; Ravi Ranjan Raj

doi:10.55544/jrasb.3.3.25

Authors

Anamika Assistant Professor, Department of Pharmacy, Shree Dev Bhoomi Institute of Education Science and Technology, Dehradun, INDIA.
Roshan Kumar Assistant Professor, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Dehradun, INDIA.
Subham Kumar Assistant Professor, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Dehradun, INDIA.
Priya Singh Assistant Professor, Department of Pharmacy, Kingston Imperial Institute of Science and Technology, Dehradun, INDIA.
Puja Kumari Assistant Professor, SNS College of Pharmacy, Motihari, Bihar, INDIA.
Abhishek Kumar Research Scholar, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, INDIA.
Rajeev Ranjan Raj Research Scholar, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, INDIA.
Kritika Singh Research Scholar, Shree Dev Bhoomi Institute of Education Science and Technology, Dehradun, INDIA.
Ravi Ranjan Raj Research Scholar, Rani Durgawati Vishwavidyalaya, Saraswati Vihar, Pachpedi, Jabalpur, Madhya Pradesh, INDIA.

DOI:

https://doi.org/10.55544/jrasb.3.3.25

Keywords:

ICH, Hypertension, Blood pressure, HPLC

Abstract

The devised method passed the ICH Q2 (R1) validation test, and the findings imply it might be utilised for both the regular monitoring of pharmaceutical formulation and raw material quality. Results for Nebivolol and Hydrochlorothiazide were consistently linear across concentration ranges of 4-24 and 10-60 μg/mL, respectively, according to the linearity study. The proposed approach was determined to be appropriate based on precision data and minimal relative standard deviation (RSD). Our lab confirmed the LOD and LOQ values for cilnidipine and lisinopril dihydrate. The method's accuracy within the given range is demonstrated by the low relative standard deviation (RSD) values. We found that the suggested method was linear, sensitive, accurate, and exact when it came to estimating hydrochlorothiazide and nebivolol in bulk and in pharmaceutical formulations. This conclusion was reached when the validation inquiry was finished and the results were discovered.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 . international society of hypertension global hypertension practice guidelines. Hypertension. (2020). 75:1334–57. 10.1161/HYPERTENSIONAHA.120.15026

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. (2020) 16:223–37. 10.1038/s41581-019-0244-2

Sudharsanan N, Theilmann M, Kirschbaum TK, Manne-Goehler J, Azadnajafabad S, Bovet P, et al. Variation in the proportion of adults in need of blood pressure–lowering medications by hypertension care guideline in low- and middle-income countries. Circulation. (2021) 143:991–1001. 10.1161/CIRCULATIONAHA.120.051620

Fang J, Chang T, Wang G, Loustalot F. Association between cost-related medication nonadherence and hypertension management among us adults. Am J Hypert. (2020) 33:879–86. 10.1093/ajh/hpaa072

Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension. (2021) 77:692–705. 10.1161/HYPERTENSIONAHA.120.15781

Campana E, Cunha V, Glaveckaite S, Gruev I, Lamirault G, Lehmann E, et al. The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. J Hypertens. (2020) 38:2369–77. 10.1097/HJH.0000000000002598

Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypert. (2020) 38:1016–28. 10.1097/HJH.0000000000002381

Segers P, Rietzschel ER, Chirinos JA. How to measure arterial stiffness in humans. Arterioscl Throm Vasc Biol. (2020) 40:1034–43. 10.1161/ATVBAHA.119.313132

Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. (2012) 308:875–81. 10.1001/2012.jama.10503

Dumor K, Shoemaker-Moyle M, Nistala R, Whaley-Connell A. Arterial stiffness in hypertension: an update. Curr Hypertens Rep. (2018) 20:72. 10.1007/s11906-018-0867-x

Chirinos JA, Segers P, Hughes T, Townsend R. Large-artery stiffness in health and disease: jacc state-of-the-art review. J Am Coll Cardiol. (2019) 74:1237–63. 10.1016/j.jacc.2019.07.012

Wilson J, Webb AJS. Systolic blood pressure and longitudinal progression of arterial stiffness: a quantitative meta-analysis. J Am Heart Assoc. (2020) 9:e017804–017804. 10.1161/JAHA.120.017804

Zanoli L, Briet M, Empana JP, Cunha PG, Mäki-Petäjä KM, Protogerou AD, et al. Vascular consequences of inflammation: a position statement from the esh working group on vascular structure and function and the artery society. J Hypertens. (2020) 38:1682–98. 10.1097/HJH.

Tocci G, Battistoni A, Passerini J, Musumeci MB, Francia P, Ferrucci A, et al. Calcium channel blockers and hypertension. J Cardiovas Pharmacol Ther. (2014) 20:121–30. 10.1177/1074248414555403

Kraehling JR, Sessa WC. Contemporary approaches to modulating the nitric oxide–cgmp pathway in cardiovascular disease. Circ Res. (2017) 120:1174–82. 10.1161/CIRCRESAHA.117.303776

Garcia V, Sessa WC. Endothelial nos: perspective and recent developments. Br J Pharmacol. (2019) 176:189–96. 10.1111/bph.14522

Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. (2018) 15:292–316. 10.1038/nrcardio.2017.224

Sanyour HJ, Li N, Rickel AP, Childs JD, Kinser CN, Hong Z. Membrane cholesterol and substrate stiffness co-ordinate to induce the remodelling of the cytoskeleton and the alteration in the biomechanics of vascular smooth muscle cells. Cardiovasc Res. (2019) 115:1369–80. 10.1093/cvr/cvy276

Gérard, A., Woolfe, A., Mottet, G., Reichen, M., Castrillon, C., Menrath, V., ... & Brenan, C. (2020). High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nature biotechnology, 38(6), 715-721.

Chattopadhyay A, Kwartler CS, Kaw K, Li Y, Kaw A, Chen J, et al. Cholesterol-induced phenotypic modulation of smooth muscle cells to macrophage/fibroblast-like cells is driven by an unfolded protein response. Arterioscler Thromb Vasc Biol. (2021) 41:302–16. 10.1161/ATVBAHA.120.315164

Yap C, Mieremet A, de Vries CJM, Micha D, de Waard V. Six shades of vascular smooth muscle cells illuminated by klf4 (krüppel-like factor 4). Arterioscler Thromb Vasc Biol. (2021) 41:2693–707. 10.1161/ATVBAHA.121.316600

Chandran RR, Xie Y, Gallardo-Vara E, Adams T, Garcia-Milian R, Kabir I, et al. Distinct roles of klf4 in mesenchymal cell subtypes during lung fibrogenesis. Nat Commun. (2021) 12:7179. 10.1038/s41467-021-27499-8

Sun D, Ding D, Li Q, Xie M, Xu Y, Liu X. The preventive and therapeutic effects of aav1-klf4-shrna in cigarette smoke-induced pulmonary hypertension. J Cell Mol Med. (2021) 25:1238–51. 10.1111/jcmm.16194

Sun D, Li Q, Ding D, Li X, Xie M, Xu Y, et al. Role of krüppel-like factor 4 in cigarette smoke-induced pulmonary vascular remodeling. Am J Transl Res. (2018) 10:581–91.

Roush GC, Sica DA. Diuretics for hypertension: a review and update. Am J Hypert. (2016) 29:1130–7. 10.1093/ajh/hpw030

Awuchi, C. G., Amagwula, I. O., Priya, P., Kumar, R., Yezdani, U., & Khan, M. G. (2020). Aflatoxins in foods and feeds: A review on health implications, detection, and control. Bull. Environ. Pharmacol. Life Sci, 9, 149-155.

Kaur, R. P., Vasudeva, K., Kumar, R., & Munshi, A. (2018). Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. Current pharmaceutical design, 24(30), 3566-3575.

Morris RC, Schmidlin O, Sebastian A, Tanaka M, Kurtz TW. Vasodysfunction that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt-induced hypertension. Circulation. (2016) 133:881–93. 10.1161/CIRCULATIONAHA.115.017923